Double-Duty immune attack tested against tough sarcoma
NCT ID NCT04095208
Summary
This study is testing whether adding a second immunotherapy drug (relatlimab) to a standard one (nivolumab) works better for controlling advanced soft tissue sarcoma. It enrolled 67 adults whose cancer has spread and is no longer responding to other treatments. Patients were randomly assigned to receive either the two-drug combination or the single drug alone to see which better stops the cancer from growing.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Léon Bérard
Lyon, 69000, France
-
Hôpital Cochin
Paris, 75014, France
-
Institut Bergonié
Bordeaux, 33000, France
-
Institut Gustave Roussy
Villejuif, 94805, France
-
Institut de Cancérologie de l'Ouest - Site René Gauducheau
Nantes, 44805, France
Conditions
Explore the condition pages connected to this study.